Loading data for DYN — first visit, this takes a few seconds.

Dyne Therapeutics, Inc. (DYN)

NasdaqGS: DYN · 即時價格 · USD

24.28

-0.67 (-2.69%)

收盤價： Sep 04, 2026, 3:59 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-2.69% (1D)

買價	17.64
市值	4.69B
營收 (ttm)	n/a
淨利（ttm）	-519M
	1.08
	-3.26
	n/a
	-7.51
P/B (ttm)	5.92
P/S (ttm)	0.00
財報日期	Nov 5, 2026

賣價	31.19
成交量	1,588,032
20 日平均成交量	2,226,971
開盤價	24.59
前收盤價	24.95
當日區間	24.14 - 24.70
52 週範圍	11.92 - 27.30
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 DYN

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases usin...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Sep 17, 2020

員工 289

證券交易所 NasdaqGS

股票代號 DYN

網站 https://www.dyne-tx.com

完整的公司簡介

財務表現

Dyne Therapeutics 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -446.21M，較前期增加 40.58%。

財務報表

財報驚奇

Dyne Therapeutics 已於 Jul 29, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -1.08 低於預期 -0.33, 年增 -11.34% 下滑.

下次財報發布

Dyne Therapeutics, Inc. 的下次財報預計於 Nov 5, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 月前 · Simply Wall St.

Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?

Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest ana...

1 月前 · Zacks

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

1 月前 · MT Newswires

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Major Tech Earnings

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) retreated 0.4%, and the actively

1 月前 · InvestorsHub

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)

Discounted share sale weighs on stockDyne Therapeutics, Inc. (NASDAQ:DYN) shares fell 9% on Wednesday after the biotechnology company priced a public offering of common stock expected to raise approxi...

1 月前 · Stocktwits

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.

第 1 頁，共 2 頁

Dyne Therapeutics, Inc. (DYN)